Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome

Blood

Volumn 100, Issue 13, 2002, Pages 4337-4343

  Richardson, Paul G ^{a,b,c,d,e,f,g,h}   Murakami, Carol ^{a,b,c,d,e,f,g}   Jin, Zhezhen ^{a,b,c,d,e,f,g}   Warren, Diane ^{a,b,c,d,e,f,g}   Momtaz, Parisa ^{a,b,c,d,e,f,g}   Hoppensteadt, Deborah ^{a,b,c,d,e,f,g}   Elias, Anthony D ^{a,b,c,d,e,f,g}   Antin, Joseph H ^{a,b,c,d,e,f,g}   Soiffer, Robert ^{a,b,c,d,e,f,g}   Spitzer, Thomas ^{a,b,c,d,e,f,g}   Avigan, David ^{a,b,c,d,e,f,g}   Bearman, Scott I ^{a,b,c,d,e,f,g}   Martin, Paul L ^{a,b,c,d,e,f,g}   Kurtzberg, Joanne ^{a,b,c,d,e,f,g}   Vredenburgh, James ^{a,b,c,d,e,f,g}   Chen, Allen R ^{a,b,c,d,e,f,g}   Arai, Sally ^{a,b,c,d,e,f,g}   Vogelsang, Georgia ^{a,b,c,d,e,f,g}   McDonald, George B ^{a,b,c,d,e,f,g}   Guinan, Eva C ^{a,b,c,d,e,f,g}  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BILIRUBIN; CREATININE; DEFIBROTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ABDOMINAL CRAMP; ADOLESCENT; ADULT; AGE; ARTICLE; ASCITES; AUTOTRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BLEEDING; BRAIN DISEASE; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; FEMALE; FEVER; HIGH RISK POPULATION; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPOTENSION; INFANT; LIVER BLOOD FLOW; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NAUSEA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEM CELL TRANSPLANTATION; SURVIVAL; SURVIVAL TIME; TOXICITY; TREATMENT OUTCOME; VASOMOTOR DISORDER; VEIN OCCLUSION; WEIGHT GAIN;

EID: 0037114746     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1216     Document Type: Article

References (55)

1. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116-122.
2. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85:3005-3020.
3. Richardson PG, Guinan EC. The pathology, diagnosis and treatment of hepatic veno-occlusive disease: Current status and novel approaches. Br J Haematol. 1999;107:485-493.
4. Richardson P, Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol. 2001;106:57-68.
5. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Int Med. 1993;118:255-267.
6. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599-3604.
7. Shulman HM, McDonald GB, Matthews D, et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology. 1980;79:1178-1191.
8. Shulman HM, Fisher LB, Schoch HG, Kenne KW, McDonald GB. Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology. 1994;19:1171-1180.
9. DeLeve L, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27-42.
10. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation: Immunohistochemical identification of the material within occluded central venules. Am J Pathol. 1987;127:549-558.
11. Baglin TP, Harper P, Marcus RE. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant. 1990;5:439-441.
12. Ibrahim A, Pico JL, Maraninchi D, et al. Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin El. Bone Marrow Transplant. 1991;7(suppl 2):53.
13. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood. 1992;80:2458-2462.
14. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood. 1997;89:1501-1506.
15. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737-744.
16. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionateuse study. Br J Haematol. 2000;111:1122-1129.
17. Salat C, Pihusch R, Fries S, et al. Successful treatment of veno-occlusive disease with defibrotide - A report of two cases [abstract]. Bone Marrow Transplant. 1999;23:757.
18. Zinke W, Neumeister P, Linkesch W. Defibrotidean approach in the treatment of severe veno-occlusive disease? [abstract]. Bone Marrow Transplant. 1999;23:760.
19. Abecasis MM, Conceicao Silva JP, Ferreira I, Guimaraes A, Machado A. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:843-846.
20. Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol. 1988;35:151-156.
21. Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V. Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins. Prostaglandins. 1990;40:337-350.
22. Coccheri S, Biagi G. Defibrotide. Cardiovasc Drug Rev. 1991;9:172-196.
23. Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost. 1994;71:507-510.
24. Fareed J. Modulation of endothelium by heparin and related polyelectrolytes. In Nicolaides A, Novo S, eds. Advances in Vascular Pathology 1997. Amsterdam, The Netherlands: Elsevier Science; 1997.
25. Ulutin ON. Antithrombotic effect and clinical potential of defibrotide. Semin Thromb Hemost. 1993;19:186-191.
26. Jamieson A, Alcock P, Tuffin DP. The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat. Fibrinolysis. 1996;10:27-35.
27. Falanga A, Marchetti M, Vignoli A, Barbui T. Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells. Blood. 1999;94:146a.
28. Falanga A, Marchetti M, Vignoli A, Barbui T. Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cells macro- and micro-vessels [abstract]. Blood. 2000;96:53a.
29. Palmer KJ, Goa KL. Defibrotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs. 1993;45:259-294.
30. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11:1729-1736.
31. Richardson P, Bearman SI. Prevention and treatment of hepatic venocclusive disease after highdose cytoreductive therapy. Leuk Lymphoma. 1998;31:267-277.
32. Haire WD, Ruby EI, Gordon BG, et al. Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA. 1995;274:1289-1295.
33. Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: A case for evidence-based guidelines. Ann Intern Med. 1996;125:625-633.
34. Zager RA, O'Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis. 1989;13:210-216.
35. Fink J, Cooper M, Burkhart K, McDonald GB, Zager RA. Marked enzymuria following bone marrow transplantation: A correlate of veno-occlusive disease-induced "hepato-renal syndrome." J Am Soc Nephrol. 1995;6:1655-1660.
36. Bonomini V, Frasca GM, Raimondi C, D'arcangelo GL, Vangelista A. Effect of a new antithrombotic agent (Defibrotide) in acute renal failure due to thrombotic microangiopathy. Nephron. 1985;40:195-200.
37. Violi F, Marubini E, Coccheri S, Nenci G. Improvement of walking distance by defibrotide in patients with intermittent claudication - Results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study. Thromb Haemost. 2000;83:672-677.
38. Allen JR, Carstens LA, Katagiri GJ. Hepatic veins of monkeys with veno-occlusive disease: Sequential ultrastructural changes. Arch Pathol. 1969;87:279-289.
39. Shirai M, Nagashima K, Iwasaki S, Mori W. Alight and scanning electron microscopic study of hepatic veno-occlusive disease. Acta Pathol Jpn. 1987;37:1961-1971.
40. Kario K, Duell P, Matsuo T, et al. High plasma homocyst(e)ine levels in elderly Japanese patients are associated with increased cardiovascular disease risk independently from markers of coagulation activation and endothelial cell damage. Atherosclerosis. 2001;157:441-449.
41. Gemtsen ME, Bloor CM. Endothelial cell gene expression in response to injury. FASEB J. 1993;7:523-532.
42. Shulman H, Hinterberger W. Hepatic veno-occlusive disease - Liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 1992;10:197-214.
43. Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol. 1996;14:1484-1494.
44. Hassan M, Ljungman P, Ringden O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000;25:915-924.
45. Salat C, Holler E, Reinhardt B, et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant. 1994;14:747- 750.
46. Salat C, Holler E, Kolbe HJ, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood. 1997;89:2184-2188.
47. Salat C, Holler E, Kolbe HJ, et al. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. Leuk Lymphoma. 1999;33:25-32.
48. Scrobohaci ML, Drouet L, Monem-Mansi A, et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 1991;63:509-519.
49. Ferra C, de Sanjose S, Gallardo D, et al. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica. 1998;83:1082-1087.
50. Schots R, Kaufman L, Van Riet I, et al. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant. 1998;22:79-85.
51. Sato Y, Asada Y, Hara S, et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology. 1999;34:66-70.
52. Geppert A, Zorn G, Delle-Karth G, et al. Plasminogen activator inhibitor type 1 and outcome after successful cardiopulmonary resuscitation. Crit Care Med. 2001;29:1670-1677.
53. Mavrommatis A, Theodoridis T, Economou M, et al. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: Comparison with severe sepsis and septic shock. Intensive Care Med. 2001;27:1853-1859.
54. Richardson P, Warren D, Momtaz P, et al. Multi-institutional phase II randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multisystem organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population. Blood. 2001;98:853a.
55. Ringden O, Remberger M, Lehmann S, et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2000;25:993-996.